Evidence map›Paper›PMID 29736814›Full record

ArticleDrugs & aging2018

Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences.

Tomáš Bolek, Matej Samoš, Ingrid Škorňová, Lucia Stančiaková, Ján Staško, Peter Galajda, Peter Kubisz, Marián Mokáň

Abstract read
PubMed Publisher
In one paragraph

Article in Drugs & aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Dabigatran trough concentrations in very elderly patients.European journal of hospital pharmacy : science and practice · 2021
    Observational
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tomáš BolekDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic.
Matej SamošDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic. matej.samos@gmail.com.
Ingrid ŠkorňováDepartment of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Centre of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic.
Lucia StančiakováDepartment of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Centre of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic.
Ján StaškoDepartment of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Centre of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic.
Peter GalajdaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic.
Peter KubiszDepartment of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Centre of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic.
Marián MokáňDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovak Republic.
Comenius University Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of elderly individuals with non-valvular atrial fibrillation (NV-AF) requiring long-term anticoagulation is rising. The pharmacokinetics of oral anticoagulants in elderly individuals may differ from that for younger patients. The aim of this study was to assess the dabigatran levels in elderly patients with NV-AF. PATIENTS AND

methodsA pilot prospective post-marketing study in patients with NV-AF on dabigatran therapy was performed; we enrolled 21 consecutive elderly patients (aged ≥ 75 years) on a reduced dabigatran regimen (110 mg twice daily) and compared them with 13 younger (≤ 70 years) individuals on reduced dabigatran therapy due to renal impairment and with 16 younger patients on standard dabigatran therapy (150 mg twice daily). Blood samples were taken for the assessment of dabigatran trough and peak levels. Dabigatran levels were measured with the Hemoclot

resultsThere were significant differences in dabigatran trough levels when comparing elderly patients on reduced dabigatran with non-elderly patients on reduced dabigatran (99.3 ± 73.6 vs 51.6 ± 25.6 ng/mL; p < 0.01). Similarly, the detected dabigatran peak levels were significantly higher in elderly patients on reduced dabigatran compared with non-elderly patients on reduced dabigatran (173.4 ± 116.2 vs 116.1 ± 19.1 ng/mL; p < 0.01). No significant differences in dabigatran trough and peak levels were found when comparing elderly patients on reduced dabigatran with non-elderly patients on standard dabigatran therapy.

conclusionThis pilot study demonstrated that elderly patients on reduced dabigatran exhibit significantly higher dabigatran levels than younger individuals on a reduced regimen, and similar levels compared with younger individuals on standard dabigatran.

Indexed as

Administration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationDabigatranDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPilot ProjectsProspective StudiesAnticoagulantsDabigatran

Identifiers

PMID29736814
OpenAlexW2801393746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.